Investment Thesis
IO Biotech is a pre-revenue pharmaceutical company with severe financial distress, burning $61.4M in operating cash flow with only $30.7M in cash reserves, indicating a runway of approximately 6 months. The company's negative net income of -$57.0M, combined with a debt-to-equity ratio of 18.29x and stockholders' equity of only $911K, suggests imminent solvency concerns and substantial dilution risk for existing shareholders.
Strengths
- Adequate short-term liquidity with current ratio of 2.01x providing temporary operational flexibility
- Substantial cash position of $30.7M relative to total assets, though insufficient relative to burn rate
- No insider selling activity in last 90 days suggests management confidence, though absence of insider buying is notable
Risks
- Severe cash burn of $61.4M annually with only 6 months of runway at current rate, creating critical funding risk
- Pre-revenue status with no commercial product monetization despite operating as a pharmaceutical company
- Extremely high leverage with debt-to-equity of 18.29x and minimal equity cushion of $911K, indicating bankruptcy risk if cash depletes
- Negative interest coverage of -215.6x shows inability to service debt from operations
- Operating losses of -$65.1M demonstrate fundamental business model failure without path to profitability
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to assess immediate solvency timeline
- Clinical trial progress and regulatory milestones that could support future revenue potential
- Additional financing activities and dilution impact on existing shareholders
- Operating cash flow trajectory and quarterly burn rate changes
Financial Metrics
Revenue
N/A
Net Income
-57.0M
EPS (Diluted)
$-0.86
Free Cash Flow
-61.4M
Total Assets
40.0M
Cash
30.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-6,258.6%
ROA
-142.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.01x
Quick Ratio
2.01x
Debt/Equity
18.29x
Debt/Assets
97.7%
Interest Coverage
-215.59x
Long-term Debt
16.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-29T11:42:11.225274 |
Data as of: 2025-09-30 |
Powered by Claude AI